Highlights from our recent and ongoing HEOR work

This page features materials on Analysis Group, including recent work and thought leadership in HEOR. We hope that this information is helpful to you.

• Analysis Group Posters and Presentations: ISPOR Europe 2023
• Health Economics, Outcomes and Epidemiology: Published Research and Presentations

Real-World Data (RWD) & Real-World Evidence (RWE)

• Shared Learning Without Waiting for Shared Data: Using Federated Analytics for Health Care Research Across Multiple Institutions and Countries
• A New “Gold Standard”? How Digital Health Technologies Can Be Used to Monitor Patient Progress
• Quantitative Approaches to Stress-Testing Scientific Claims in Health Care
• Analysis Group Announces Real-World Evidence Study Supported Blueprint Medicines’ Label Expansion of AYVAKYT® (avapritinib) to Advanced Systemic Mastocytosis in the EU
• Analysis Group’s Real-World Data Study with Takeda Supports FDA’s Recent Exkivity™ (Mobocertinib) Approval
• Study by Analysis Group and AstraZeneca Researchers Fills Real-World Data Gap for Providers Treating Severe Asthma Sufferers
• Analysis Group Health Care Researchers Pioneer New Method for Generating Real-World Data
• Analysis Group Research Sheds Light on Regulatory Real-World Evidence in Successful Oncology Product Approvals
• Using Real-World Data to Understand Treatment Patterns and Outcomes of Blood Disease Patients in China
• Fulfilling the Promise: Real-World Data and Real-World Evidence in Action

Economic Analysis

• Analysis Group Team Coauthors Study on Health Care Resource Utilization and Costs in US Patients with GERD, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia
• The Global Carbon Footprint of Asthma Inhalers: Policy Shifts Can Reduce Emissions, Analysis Group Study Finds
• Health Care Resource Utilization Study Coauthored by Analysis Group Is First to Describe Economic Burden of MDSI
• Latest Update to 30-Year Economic Study Reveals Important Shifts in the Burden of Major Depressive Disorder

COVID-19

• Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program of US Veterans Health Administration Patients
• Study of COVID-19 in the US Quantifies Elevated Health Care Costs Associated with the Disease
• Forum: Tracking the Path of COVID-19 in Haiti
• Forum: Vaccines, Incentives, and Innovation: The Lessons of COVID-19 for the Pharmaceutical Industry

China

• Analysis Group RWE Experts Call for Actions Regarding Generating Real-World Data for Health Care Research in China
• Research from Analysis Group and IHBDH Furthers Understanding of Hemophilia in China
• Analysis Group Research Improves the Quality of Real-World Data for Blood Disease Treatment in China
• Analysis Group Team Coauthors Study on Health Technology Assessment in Asia

Click here to learn more about Analysis Group and our HEOR, Epidemiology & Market Access practice.

Learn more about career opportunities with Analysis Group’s HEOR, Epidemiology & Market Access practice here.